MiMedx Group, Inc Stock 12‑Month Price Target Cut to $7.2, Implies 82% Upside
MiMedx Group's (MDXG) average price target was reduced from $7.4 to $7.2 by 5 analysts, with a range of $6 to $8. This implies 82% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' across all analysts.
How this was made

The 30-second read
Why it matters
Analyst target cuts typically lead to short‑term price declines, especially for low‑float stocks.
Market read
The target reduction is a modest but actionable piece of news for traders holding or considering MMDX.
What to watch
Potential upcoming clinical data or partnership news could offset the target reduction.
Background
MiMedx Group is a biotech firm focused on regenerative medicine. The price‑target change comes from a consensus of five analysts.
Market effects
Minimal; the change reflects analyst sentiment on MiMedx rather than a broader sector shift.
None; the news is company‑specific.
Low; limited to investors tracking micro‑cap biotech stocks.
Counterpoint
Some investors may view the still‑large upside as a buying opportunity despite the target cut.
Key entities
- companyMiMedx Group, Inc.
Biotech company whose price target was reduced.


